1Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(12):1655-1669. https://doi.org/10.1016/S1470-2045(19)30634-5
2Nakagawa K, Nadal E, Garon EB, et al. RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non-small cell lung cancer. Clin Cancer Res. Published online July 22, 2021. https://dx.doi.org/10.1158/1078-0432.CCR-21-0273
3Nakagawa K, Nadal E, Garon EB, et al. RELAY, erlotinib plus ramucirumab in previously untreated, EGFR-mutated, metastatic NSCLC: Outcomes by EGFR mutation type. Poster presented at: Annual Meeting of the European Society for Medical Oncology (ESMO Virtual); September 19-21, 2020.
4Garon EB, Reck M, Nishio K, et al. RELAY, ramucirumab plus erlotinib (RAM+ERL) versus placebo plus erlotinib (PBO+ERL) in previously untreated EGFR mutation positive metastatic NSCLC: next generation sequencing (NGS) results. Poster presented at: American Association for Cancer Research (AACR 2020 Virtual); June 22-24, 2020.